Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.

@article{Scheer2011QuantifyingTB,
  title={Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.},
  author={R. F. J. van der Scheer and Achilles J. Fakiris and Peter A. S. Johnstone},
  journal={International journal of radiation oncology, biology, physics},
  year={2011},
  volume={80 4},
  pages={996-1001}
}
PURPOSE To better define the benefit of a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy in the treatment of esophageal and gastroesophageal cancer, we undertook a comprehensive review of the literature to derive a pooled analysis of crude survival data and quantify the survival benefit of pCR vs. residual disease at esophagectomy. METHODS AND MATERIALS In all, 22 articles were reviewed. Crude overall survival data, stratified by patients with pCR vs. those with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2013
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…